CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies

Journal of Neurochemistry

Volumn 127, Issue 5, 2013, Pages 681-690

  Luo, Xinni ^a   Hou, Le ^a   Shi, Haishan ^a   Zhong, Xiaomei ^a   Zhang, Yufeng ^a   Zheng, Dong ^a   Tan, Yan ^a   Hu, Guoyan ^a   Mu, Nan ^a   Chan, Jianping ^a   Chen, Xinru ^a   Fang, Yaxiu ^a   Wu, Fengchun ^a   He, Hongbo ^a   Ning, Yuping ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

synuclein; Alzheimer's disease; biomarkers; cerebrospinal fluid; dementia with Lewy bodies; VILIP 1

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; UNCLASSIFIED DRUG; VISININ LIKE PROTEIN 1;

ADULT; AGED; ALZHEIMER DISEASE; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NERVE INJURY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; VISININ LIKE PROTEIN 1 AMYLOID BETA PROTEIN[1-42] RATIO;

ALZHEIMER'S DISEASE; BIOMARKERS; CEREBROSPINAL FLUID; DEMENTIA WITH LEWY BODIES; VILIP-1; Α-SYNUCLEIN;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; NEUROCALCIN; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; ROC CURVE; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84887612435     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12331     Document Type: Article

References (57)

1. Bernstein H. G., Baumann B., Danos P., Diekmann S., Bogerts B., Gundelfinger E. D., and, Braunewell K. H., (1999) Regional and cellular distribution of neural visinin-like protein immunoreactivities (VILIP-1 and VILIP-3) in human brain. J. Neurocytol. 28, 655-662.
2. Bertram L., Lill C. M., and, Tanzi R. E., (2010) The genetics of Alzheimer disease: back to the future. Neuron 68, 270-281.
3. Bibl M., Mollenhauer B., Esselmann H., et al,. (2006) CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129, 1177-1187.
4. Bibl M., Esselmann H., Lewczuk P., Trenkwalder C., Otto M., Kornhuber J., Wiltfang J., and, Mollenhauer B,. (2010) Combined Analysis of CSF Tau, Abeta42, Abeta1-42% and Abeta1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. Int. J. Alzheimers. Dis. 2010 doi: 10.4061/2010/761571.
5. Blandini F., Braunewell K. H., Manahan-Vaughan D., Orzi F., and, Sarti P., (2004) Neurodegeneration and energy metabolism: from chemistry to clinics. Cell Death Differ. 11, 479-484.
6. Braunewell K. H., (2012) The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer's disease-old wine in new bottles. Front. Mol. Neurosci. 5, 20.
7. Braunewell K., Riederer P., Spilker C., Gundelfinger E. D., Bogerts B., and, Bernstein H. G., (2001) Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement. Geriatr. Cogn. Disord. 12, 110-116.
8. Bravo G., and, Hebert R., (1997) Age- and education-specific reference values for the Mini-Mental and modified Mini-Mental State Examinations derived from a non-demented elderly population. Int. J. Geriatr. Psychiatry 12, 1008-1018.
9. Buerger K., Ewers M., Andreasen N., et al,. (2005) Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 65, 1502-1503.
10. Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M. R., and, Sudhof T. C., (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663-1667.
11. Clinton L. K., Blurton-Jones M., Myczek K., Trojanowski J. Q., and, LaFerla F. M., (2010) Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J. Neurosci. 30, 7281-7289.
12. Crum R. M., Anthony J. C., Bassett S. S., and, Folstein M. F., (1993) Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 269, 2386-2391.
13. Dickson D. W., (2002) Dementia with Lewy bodies: neuropathology. J. Geriatr. Psychiatry Neurol. 15, 210-216.
14. Dubois B., Feldman H. H., Jacova C., et al,. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746.
15. Engelborghs S., and, Le Bastard N., (2012) The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Mol. Diagn. Ther. 16, 135-141.
16. Giasson B. I., Forman M. S., Higuchi M., Golbe L. I., Graves C. L., Kotzbauer P. T., Trojanowski J. Q., and, Lee V. M., (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636-640.
17. Gitler A. D., Bevis B. J., Shorter J., et al,. (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl Acad. Sci. USA 105, 145-150.
18. Hansen L. A., and, Samuel W., (1997) Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology 48, 126-132.
19. Hettiarachchi N. T., Parker A., Dallas M. L., Pennington K., Hung C. C., Pearson H. A., Boyle J. P., Robinson P., and, Peers C., (2009) alpha-Synuclein modulation of Ca2 + signaling in human neuroblastoma (SH-SY5Y) cells. J. Neurochem. 111, 1192-1201.
20. Hort J., Bartos A., Pirttila T., and, Scheltens P., (2010) Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur. J. Neurol. 17, 90-96.
21. Jack C. R., Jr, Albert M. S., Knopman D. S., McKhann G. M., Sperling R. A., Carrillo M. C., Thies B., and, Phelps C. H., (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 257-262.
22. Kasuga K., Tokutake T., Ishikawa A., Uchiyama T., Tokuda T., Onodera O., Nishizawa M., and, Ikeuchi T., (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 81, 608-610.
23. Laterza O. F., Modur V. R., Crimmins D. L., Olander J. V., Landt Y., Lee J. M., and, Ladenson J. H., (2006) Identification of novel brain biomarkers. Clin. Chem. 52, 1713-1721.
24. Lee V. M., Goedert M., and, Trojanowski J. Q., (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159.
25. Lee V. M., Giasson B. I., and, Trojanowski J. Q., (2004) More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci. 27, 129-134.
26. Lee J. M., Blennow K., Andreasen N., Laterza O., Modur V., Olander J., Gao F., Ohlendorf M., and, Ladenson J. H., (2008) The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin. Chem. 54, 1617-1623.
27. Mandal P. K., Pettegrew J. W., Masliah E., Hamilton R. L., and, Mandal R., (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem. Res. 31, 1153-1162.
28. Maroteaux L., Campanelli J. T., and, Scheller R. H,. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815.
29. Martinez J., Moeller I., Erdjument-Bromage H., Tempst P., and, Lauring B., (2003) Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. J. Biol. Chem. 278, 17379-17387.
30. Mattson M. P., (2007) Calcium and neurodegeneration. Aging Cell 6, 337-350.
31. McKeith I. G., Dickson D. W., Lowe J., et al,. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872.
32. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and, Stadlan E. M., (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
33. Mollenhauer B., Cepek L., Bibl M., et al,. (2005) Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement. Geriatr. Cogn. Disord. 19, 164-170.
34. Mollenhauer B., El-Agnaf O. M., Marcus K., Trenkwalder C., and, Schlossmacher M. G., (2010) Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark. Med. 4, 683-699.
35. Mollenhauer B., Locascio J. J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C., and, Schlossmacher M. G., (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230-240.
36. Nejatbakhsh N., and, Feng Z.-P., (2011) Calcium binding protein-mediated regulation of voltage-gated calcium channels linked to human diseases. Acta Pharmacol. Sin. 32, 741-748.
37. Nelson P. T., Jicha G. A., Kryscio R. J., Abner E. L., Schmitt F. A., Cooper G., Xu L. O., Smith C. D., and, Markesbery W. R., (2010) Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J. Neurol. 257, 359-366.
38. Ohrfelt A., Grognet P., Andreasen N., Wallin A., Vanmechelen E., Blennow K., and, Zetterberg H., (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci. Lett. 450, 332-335.
39. Querfurth H. W., and, LaFerla F. M., (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329-344.
40. Scherzer C. R., Grass J. A., Liao Z., et al,. (2008) GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc. Natl Acad. Sci. USA 105, 10907-10912.
41. Schnurra I., Bernstein H. G., Riederer P., and, Braunewell K. H., (2001) The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? Neurobiol. Dis. 8, 900-909.
42. Schulz-Schaeffer W. J., (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 120, 131-143.
43. Shaw L. M., Vanderstichele H., Knapik-Czajka M., et al,. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403-413.
44. Snider B. J., Fagan A. M., Roe C., Shah A. R., Grant E. A., Xiong C., Morris J. C., and, Holtzman D. M., (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch. Neurol. 66, 638.
45. Spilker C., and, Braunewell K. H., (2003) Calcium-myristoyl switch, subcellular localization, and calcium-dependent translocation of the neuronal calcium sensor protein VILIP-3, and comparison with VILIP-1 in hippocampal neurons. Mol. Cell. Neurosci. 24, 766-778.
46. Stejskal D., Sporova L., Svestak M., and, Karpisek M., (2011) Determination of serum visinin like protein-1 and its potential for the diagnosis of brain injury due to the stroke: a pilot study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub 155, 263-268.
47. Stomrud E., Hansson O., Zetterberg H., Blennow K., Minthon L., and, Londos E., (2010) Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch. Neurol. 67, 217-223.
48. Sunderland T., Linker G., Mirza N,. et al. (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094-2103.
49. Tapiola T., Alafuzoff I., Herukka S. K., Parkkinen L., Hartikainen P., Soininen H., and, Pirttila T., (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66, 382-389.
50. Tarawneh R., D'Angelo G., Macy E., et al,. (2011) Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann. Neurol. 70, 274-285.
51. Tarawneh R., Lee J. M., Ladenson J. H., Morris J. C., and, Holtzman D. M., (2012) CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78, 709-719.
52. Trojanowski J. Q., and, Lee V. M., (2002) Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. Neurotoxicology 23, 457-460.
53. Tymianski M., and, Tator C. H., (1996) Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Neurosurgery 38, 1176-1195.
54. Wallin A. K., Blennow K., Andreasen N., and, Minthon L., (2006) CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement. Geriatr. Cogn. Disord. 21, 131-138.
55. Wenham P. R., Price W. H., and, Blandell G., (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337, 1158-1159.
56. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. (1998) Consensus report of the working group on: "Molecular and biochemical markers of alzheimer's disease". Neurobiol. Aging, 19, 109-116.
57. Zhang Z. X., Zahner G. E., Roman G. C., et al,. (2005) Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch. Neurol. 62, 447-453.